newsfilter
← Latest News
Business Wire·

CEL-SCI Presents New Phase 3 Multikine® Data at World Congress: Pre-Surgical Biomarkers Identify Head & Neck Cancer Patients Achieving 73% 5-Year Survival

Target Population Selection: Biomarker profile – applied prior to treatment of locally advanced disease with no lymph node involvement (N0) and low/zero tumor PD-L1 expression (TPS <10%) or zero identifies patients